137 related articles for article (PubMed ID: 25387885)
41. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK
Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321
[TBL] [Abstract][Full Text] [Related]
42. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer.
Ko ES; Han BK; Kim RB; Ko EY; Shin JH; Hahn SY; Nam SJ; Lee JE; Lee SK; Im YH; Park YH
Ann Surg Oncol; 2013 Aug; 20(8):2562-8. PubMed ID: 23463090
[TBL] [Abstract][Full Text] [Related]
43. Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials.
Loibl S; Jackisch C; Lederer B; Untch M; Paepke S; Kümmel S; Schneeweiss A; Huober J; Hilfrich J; Hanusch C; Gerber B; Eidtmann H; Denkert C; Costa SD; Blohmer JU; Nekljudova V; Mehta K; von Minckwitz G
Breast Cancer Res Treat; 2015 Jul; 152(2):377-87. PubMed ID: 26109347
[TBL] [Abstract][Full Text] [Related]
44. Prediction of Pathologic Complete Response in Breast Cancer Patients Comparing Magnetic Resonance Imaging with Ultrasound in Neoadjuvant Setting.
Palshof FK; Lanng C; Kroman N; Benian C; Vejborg I; Bak A; Talman ML; Balslev E; Tvedskov TF
Ann Surg Oncol; 2021 Nov; 28(12):7421-7429. PubMed ID: 34043094
[TBL] [Abstract][Full Text] [Related]
45. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
[TBL] [Abstract][Full Text] [Related]
46. Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy.
Schott AF; Roubidoux MA; Helvie MA; Hayes DF; Kleer CG; Newman LA; Pierce LJ; Griffith KA; Murray S; Hunt KA; Paramagul C; Baker LH
Breast Cancer Res Treat; 2005 Aug; 92(3):231-8. PubMed ID: 16155794
[TBL] [Abstract][Full Text] [Related]
47. Ultrasound-based radiomics for early predicting response to neoadjuvant chemotherapy in patients with breast cancer: a systematic review with meta-analysis.
Li Z; Liu X; Gao Y; Lu X; Lei J
Radiol Med; 2024 Jun; 129(6):934-944. PubMed ID: 38630147
[TBL] [Abstract][Full Text] [Related]
48. RECIST for Response (Clinical and Imaging) in Neoadjuvant Clinical Trials in Operable Breast Cancer.
Semiglazov V
J Natl Cancer Inst Monogr; 2015 May; 2015(51):21-3. PubMed ID: 26063880
[TBL] [Abstract][Full Text] [Related]
49. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
50. Does the time from diagnostic biopsy to neoadjuvant chemotherapy affect the rate of pathologic complete response in stages I-III breast cancer?
Le D; Eslami M; Li H; Hajjaj O; Chia S; Simmons C
Curr Oncol; 2020 Jun; 27(3):e265-e270. PubMed ID: 32669932
[TBL] [Abstract][Full Text] [Related]
51. Early prediction of pathological complete response in luminal B type neoadjuvant chemotherapy-treated breast cancer patients: comparison between interim 18F-FDG PET/CT and MRI.
Pahk K; Kim S; Choe JG
Nucl Med Commun; 2015 Sep; 36(9):887-91. PubMed ID: 25932536
[TBL] [Abstract][Full Text] [Related]
52. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.
Untch M; Loibl S; Bischoff J; Eidtmann H; Kaufmann M; Blohmer JU; Hilfrich J; Strumberg D; Fasching PA; Kreienberg R; Tesch H; Hanusch C; Gerber B; Rezai M; Jackisch C; Huober J; Kühn T; Nekljudova V; von Minckwitz G; ;
Lancet Oncol; 2012 Feb; 13(2):135-44. PubMed ID: 22257523
[TBL] [Abstract][Full Text] [Related]
53. [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer].
Li D; Chen JH; Wang J; Ling R; Yao Q; Wang L
Ai Zheng; 2007 Aug; 26(8):900-4. PubMed ID: 17697556
[TBL] [Abstract][Full Text] [Related]
54. [Comparison of response evaluation methods of neoadjuvant chemotherapy in breast cancer patients].
Sun B; Song ST; Wu SK; Jiang ZF; Wang T; Zhang SH; Zhao YB; Yu CZ; Li XB; Yang T; Li GJ
Zhonghua Zhong Liu Za Zhi; 2009 Oct; 31(10):783-5. PubMed ID: 20021835
[TBL] [Abstract][Full Text] [Related]
55. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
56. Dynamic contrast-enhanced MRI texture analysis for pretreatment prediction of clinical and pathological response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Teruel JR; Heldahl MG; Goa PE; Pickles M; Lundgren S; Bathen TF; Gibbs P
NMR Biomed; 2014 Aug; 27(8):887-96. PubMed ID: 24840393
[TBL] [Abstract][Full Text] [Related]
57. Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy.
Bossuyt V; Symmans WF
Ann Surg Oncol; 2016 Oct; 23(10):3153-61. PubMed ID: 27380637
[TBL] [Abstract][Full Text] [Related]
58. Sentinel lymph node biopsy is a reliable method for lymph node evaluation in neoadjuvant chemotherapy-treated patients with breast cancer.
Koslow SB; Eisenberg RE; Qiu Q; Chen Z; Swistel A; Shin SJ
Am Surg; 2014 Feb; 80(2):171-7. PubMed ID: 24480218
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of tumor stiffness by elastography is predictive for pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer.
Hayashi M; Yamamoto Y; Ibusuki M; Fujiwara S; Yamamoto S; Tomita S; Nakano M; Murakami K; Iyama K; Iwase H
Ann Surg Oncol; 2012 Sep; 19(9):3042-9. PubMed ID: 22476757
[TBL] [Abstract][Full Text] [Related]
60. MRI predictive factors for tumor response in rectal cancer following neoadjuvant chemoradiation therapy--implications for induction chemotherapy?
Yu SK; Tait D; Chau I; Brown G
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):505-11. PubMed ID: 24074924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
